Cartesian Therapeutics Inc. (RNAC) Stock Analysis — PE Ratio, PS Ratio, Intrinsic Value & 2030 Price Target
Cartesian Therapeutics Inc. stock (RNAC) is currently trading at $6.07. Cartesian Therapeutics Inc. PS ratio (Price-to-Sales) is 62.55. Analyst consensus price target for RNAC is $35.57. WallStSmart rates RNAC as Sell.
- RNAC PE ratio analysis and historical PE chart
- RNAC PS ratio (Price-to-Sales) history and trend
- RNAC intrinsic value — DCF, Graham Number, EPV models
- RNAC stock price prediction 2025 2026 2027 2028 2029 2030
- RNAC fair value vs current price
- RNAC insider transactions and insider buying
- Is RNAC undervalued or overvalued?
- Cartesian Therapeutics Inc. financial analysis — revenue, earnings, cash flow
- RNAC Piotroski F-Score and Altman Z-Score
- RNAC analyst price target and Smart Rating
Cartesian Therapeutics Inc.
📊 No data available
Try selecting a different time range
Smart Analysis
Cartesian Therapeutics Inc. (RNAC) · 8 metrics scored
Smart Score
Category Performance
WallStSmart pulls financial metrics like revenue growth, profit margins, and valuation ratios and scores each one from 0 to 10 based on how strong or weak it is. Those 10 scores are grouped into 4 categories: Growth, Profitability, Valuation, and Quality — which form the 4 axes of the spider chart you see. The categories are then combined into a final score out of 100, but not equally. Growth and Profitability together count for 60% of the total, because a fast-growing profitable business matters more than just a cheap one. That final number maps to a rating (Strong Buy, Buy, Hold, Avoid) and a letter grade, giving you one clear Stock Rating.
Investment Thesis
Concerns around market cap and return on equity. Significant fundamental concerns warrant caution or avoidance.
Cartesian Therapeutics Inc. (RNAC) Key Strengths (0)
Supporting Valuation Data
Cartesian Therapeutics Inc. (RNAC) Areas to Watch (8)
Company is destroying shareholder value
Losing money on operations
Earnings declining -7.40%, profits shrinking
Very expensive at 62.5x annual revenue
Very expensive at 31.3x book value
Micro-cap company with very limited liquidity and high volatility
Low institutional interest, mostly retail-driven
Solid revenue growth at 16.80% per year
Supporting Valuation Data
Cartesian Therapeutics Inc. (RNAC) Detailed Analysis Report
Overall Assessment
This company scores 16/100 in our Smart Analysis, earning a F grade. Out of 8 metrics analyzed, 0 register as strengths (avg 0/10) while 8 fall into concern territory (avg 2.1/10). The category breakdown reveals uneven performance, with some areas requiring attention.
The Bull Case
Limited fundamental strengths were identified. The bull case requires improvement in core metrics.
The Bear Case
The primary concerns are Return on Equity, Operating Margin, EPS Growth. Some valuation metrics including Price/Sales (62.55), Price/Book (31.26) suggest expensive pricing. Growth concerns include Revenue Growth at 16.80%, EPS Growth at -7.40%, which may limit upside. Profitability pressure is visible in Return on Equity at -7029.00%, Operating Margin at -2317.00%.
Key Dynamics to Monitor
Three factors to monitor going forward. First, whether Return on Equity improves, as this is the primary drag on the overall score. Second, margin trajectory, with Return on Equity at -7029.00% needing improvement to support the investment thesis. Third, growth sustainability, with Revenue Growth at 16.80% needing to reaccelerate.
Risk Considerations
Based on the metric profile, this is a higher risk investment. There are more areas of concern than strength, warranting a more conservative position size. Investors should size positions according to their risk tolerance and maintain diversification.
Bottom Line
Fundamental challenges outweigh strengths at current levels. Return on Equity and Operating Margin are the primary drags. Consider waiting for meaningful improvement before committing capital.
Disclaimer: Smart Analysis is a scoring system developed by WallStSmart Team. Scores update daily using multi-model valuation framework. Always conduct your own research and consult with financial advisors before making investment decisions.
RNAC Price-to-Sales(PS) Ratio Chart
Historical valuation based on market cap ÷ trailing 12-month revenue
RNAC's Price-to-Sales ratio of 62.55x trades at a deep discount to its historical average of 150.22x (79th percentile). The current valuation is 97% below its historical high of 1953.41x set in Sep 2018, and 38994% above its historical low of 0.16x in Dec 2023. Over the past 12 months, the PS ratio has expanded from ~9.7x, reflecting growing market expectations outpacing revenue growth.
WallStSmart Analysis Synopsis
Data-driven financial summary for Cartesian Therapeutics Inc. (RNAC) · HEALTHCARE › BIOTECHNOLOGY
The Big Picture
Cartesian Therapeutics Inc. is a strong growth company balancing expansion with improving profitability. Revenue reached 3M with 17% growth year-over-year.
Key Findings
Spending 525% of revenue (15M) on R&D, reinforcing its commitment to innovation and future growth.
Free cash flow is -18M, meaning the company is burning cash. This may be acceptable for high-growth companies investing heavily.
What to Watch Next
Sector dynamics: monitor BIOTECHNOLOGY industry trends, competitive moves, and regulatory changes that could impact Cartesian Therapeutics Inc..
Bottom Line
Cartesian Therapeutics Inc. offers an attractive blend of growth (17% revenue expansion) and improving fundamentals. The company is transitioning from pure growth to profitable growth, a critical inflection point. Watch for sustained margin expansion as the key signal.
This synopsis is generated from publicly available financial data. It is not financial advice. Always conduct your own research and consult a qualified financial advisor before making investment decisions.
Insider Transactions
Data sourced from SEC Form 4 filings
Last updated: 10:02:16 AM
About Cartesian Therapeutics Inc.(RNAC)
NASDAQ
HEALTHCARE
BIOTECHNOLOGY
USA
Selecta Biosciences, Inc., a clinical-stage biopharmaceutical company, engages in the research and development of nanoparticle immunomodulatory drugs for the treatment and prevention of human diseases. The company is headquartered in Watertown, Massachusetts.